Lophora
Private Company
Funding information not available
Overview
Lophora is a Danish private biotech company pioneering next-generation psychedelic-inspired therapeutics for central nervous system disorders. Its core technology is a rational drug design platform focused on creating selective 5-HT2A receptor agonists with optimized drug-like properties. The company's lead asset, LPH-5, has successfully completed Phase I trials, positioning it as a potential rapid-acting, non-hallucinogenic treatment for major depressive disorder and other conditions. Lophora is backed by notable Danish public funders and experienced biotech investors.
Technology Platform
Rational drug design platform for creating highly selective serotonin 5-HT2A receptor agonists with optimized drug-like properties and reduced off-target activity, aiming for sub-perceptual (non-hallucinogenic) dosing.
Opportunities
Risk Factors
Competitive Landscape
Lophora operates in a highly competitive landscape with well-funded public companies (e.g., Compass Pathways, Cybin, Atai Life Sciences) and other biotechs also developing 5-HT2A-targeting therapies. Its differentiation is its focus on highly selective, sub-perceptual agonists designed for conventional dosing, positioning it in the 'next-generation' segment of the market.